Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

NCT07388563 · clinicaltrials.gov ↗

PHASE1

Phase

SUSPENDED

Status

20

Enrollment

NIH

Sponsor class

Stopped New recruitment on hold for a protocol design amendment/modification.

Conditions

Lymphoma, T Cell, Peripheral
T-cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Anaplastic Large Cell Lymphoma
Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
Adult T-cell Leukemia/Lymphoma

Interventions

DRUG: azacitidine
DRUG: abatacept

Sponsor

National Cancer Institute (NCI)